MM-299: Fibroblast Growth Factor 23 in Multiple Myeloma Patients with Renal Impairment

Abstract

Context Intact fibroblast growth factor (iFGF23) is a 32 kDa factor containing 251 amino acids and belongs to the FGF family. iFGF23 is thought to increase the renal excretion of phosphates and decrease vitamin D levels. It is a novel factor introduced to the medical field, and the increased expression of iFGF23 has been reported in renal impairment and multiple myeloma. Objective To measure the level of serum iFGF23 in multiple myeloma patients with renal impairment and to investigate its possible predictive role in multiple myeloma patients with renal impairment. Design Cross-sectional comparative study. Setting Clinical Hematology and Bone Marrow Transplantation Unit, Ain Shams University Hospital, Cairo, Egypt. Patients and Method 80 subjects were classified into 4 groups. Group 1: 20 multiple myeloma patients with renal impairment (on dialysis and not on dialysis). Group 2: 20 multiple myeloma patients without renal impairment. Group 3: 30 healthy controls who were group-matched with patients for age and sex. Group 4: 10 non-multiple myeloma patients with renal impairment. Results Serum iFGF23 was higher in patients with multiple myeloma than in healthy controls (p Conclusion iFGF23 was observed to be associated with renal disease in multiple myeloma patients, so it may have predictive value as a biomarker, especially in multiple myeloma patients with renal impairment. Moreover, it could be used as a targetable marker for therapeutic intervention.